Skip to Content
Merck

A prospective, 1-year follow-up study of postural tachycardia syndrome.

Mayo Clinic proceedings (2012-07-17)
Kurt Kimpinski, Juan J Figueroa, Wolfgang Singer, David M Sletten, Valeria Iodice, Paola Sandroni, Philip R Fischer, Tonette L Opfer-Gehrking, Jade A Gehrking, Phillip A Low
ABSTRACT

To prospectively evaluate patients who met standard criteria for postural tachycardia syndrome (POTS), at baseline and 1-year follow-up, using standard clinical and laboratory methods to assess autonomic function. Fifty-eight patients met the study criteria (orthostatic symptoms and a heart rate increment of ≥ 30 beats/min on head-up tilt) and completed 12 months of follow-up. All patients were enrolled and completed the study from January 16, 2006, through April 15, 2009. Patients underwent standardized autonomic testing, including head-up tilt, clinical assessment, and validated questionnaires designed to determine the severity of autonomic symptoms. Patients were predominantly young females (n=49, 84%), with 20 patients (34%) reporting an antecedent viral infection before onset of symptoms. More than one-third (37%) no longer fulfilled tilt criteria for POTS on follow-up, although heart rate increment on head-up tilt did not differ significantly at 1 year (33.8 ± 15.1 beats/min) compared with baseline (37.8 ± 14.6 beats/min) for the entire cohort. Orthostatic symptoms improved in most patients. Autonomic dysfunction was mild as defined by a Composite Autonomic Severity Score of 3 or less in 55 patients (95%) at baseline and 48 patients (92%) at 1 year. To our knowledge, this is the first prospective study of the clinical outcomes of patients with POTS. Orthostatic symptoms improved in our patients, with more than one-third of patients no longer fulfilling tilt criteria for POTS, although the overall group change in heart rate increment was modest. Our data are in keeping with a relatively favorable prognosis in most patients with POTS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pyridostigmine bromide
SKU
Pack Size
Availability
Price
Quantity
Pyridostigmine bromide, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Nadolol, analytical standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Midodrine hydrochloride, analytical standard, for drug analysis
SKU
Pack Size
Availability
Price
Quantity